Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis (Q33391880)

26 July 2017

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis (English)

1 reference

26 July 2017

1 reference

1 reference

2

Hagop Kantarjian

1 reference

26 July 2017

7

Zeev Estrov

1 reference

26 July 2017

1

Srdan Verstovsek

1 reference

26 July 2017

13

Ayalew Tefferi

1 reference

ORCID Public Data File 2021

26 July 2017

1 reference

Ruben Mesa

3

object named as

Ruben A Mesa

1 reference

26 July 2017

4

Animesh D Pardanani

1 reference

26 July 2017

Susan Erickson-Viitanen

10

object named as

Susan Erickson-Viitanen

1 reference

26 July 2017

11

Kris Vaddi

1 reference

26 July 2017

Jorge E Cortes-Franco

5

object named as

Jorge Cortes-Franco

1 reference

26 July 2017

8

Jordan S Fridman

1 reference

26 July 2017

Deborah A Thomas

6

1 reference

26 July 2017

Edward C Bradley

9

1 reference

26 July 2017

Richard Levy

12

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

The New England Journal of Medicine

26 July 2017

1 reference

26 July 2017

363

1 reference

26 July 2017

12

1 reference

26 July 2017

1117-1127

1 reference

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

Therapeutic potential of JAK2 inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

Crossroads of cytokine signaling--the chase to stop muscle cachexia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

New insights into the pathogenesis and drug treatment of myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

The role of cytokines in cancer-related fatigue

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5187954

Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases

31 October 2018

1 reference

12 December 2020

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

Myelofibrosis with myeloid metaplasia

1 reference

12 December 2020

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1002028

1 reference

26 July 2017

1 reference

26 July 2017

1 reference